Promising responses seen with Agios leukemia drug in study

(Reuters) - Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.